Becton Dickinson (BD) announced that it has received 510(k) clearance from the U.S. Federal Drug Administration for its groundbreaking blood-collection device. The BD MiniDraw Capillary Blood Collection System has revolutionized the process of obtaining blood samples by allowing fingersticks to produce high-quality results.
With this innovative device, blood can now be drawn by trained healthcare workers, eliminating the need for specialized phlebotomists. This breakthrough not only offers a less invasive alternative to traditional blood-collection methods but also enables blood collection in more convenient locations such as retail pharmacies.
The 510(k) clearances secured by BD include blood collection for a lipid panel, certain chemistry tests, and hemoglobin and hematocrit testing, which are among the most commonly ordered lab tests. Moreover, BD has ambitious plans to expand the range of blood tests that can be performed using this revolutionary device in the future.
In conclusion, Becton Dickinson's BD MiniDraw Capillary Blood Collection System represents a significant advancement in the field of blood collection. With its ability to deliver lab-quality results through a minimally invasive procedure, this device promises to enhance patient comfort and convenience while streamlining healthcare processes.
